Boston Scientific Announces the approval and marketing in Europe of the coronary stent for cromo platino OMEGA (TM).

Natick, Massachusetts, March of 2011. Boston Scientific Corporation (NYSE: BS) announced on Monday the acquisition of the CE marking to the coronary stent for cromo-platino OMEGA (TM), which is for the company technology of third generation of coronary stents. OMEGA incorporates a unique alloy of cromo-platino (PtCr), designed specifically for coronary stents, and aims to provide the interventionist cardiologists metallic stent for best performance for the treatment of patients with atherosclerosis. The company will start marketing OMEGA immediately in the European Union and other countries for the application of the CE marking.

“In my experience, cromo-platino alloy and OMEGA stent design offer an excellent seaworthiness, visibility and flexibility, allowing at the same time improve the radial force and the recoil”, says Dr. Antonio Colombo, Director of the laboratory of cardiac catheterization at Columbus Hospital and Hospital San Raffaele in MilanItaly. “OMEGA and cromo-platino alloy offer significant improvements in performance, without the disadvantages associated with the alloys normally used in stents.

“OMEGA is part of the family of stents Boston Scientific cromo-platino the PROMUS Element â„¢ everolimus-eluting stent and TAXUS r Element Tm paclitaxel-eluting stent. The three have the novel alloy of PtCr and an innovative design, which combine to offer a greater radial strength and flexibility, while minimizing the recoil of the stent. The highest density of alloy provides better visibility, allowing at the same time reducing the profile of the legs of the stent compared to previous generations. The release also has been optimized, consists of a double-layer ball designed to improve access to the most difficult injury.

“Cromo-platino PROMUS Element and Element TAXUS stent have received a positive response from physicians since its launch in countries for the application of the CE marking, and we now have the pleasure of presenting a metallic coronary stent, based on the same platform of PtCr,” says Mike Phalen, Executive Vice President and President International of Boston Scientific. “OMEGA is the latest example of our commitment” innovation continued in the area of coronary stents. “”We are convinced that our cromo-platino stent technology will strengthen our leadership in the market of the stent coronary.”

“Positive clinical data from our studies with stents of ≪ PtCr (Element)
confirm the beneficial effects of our new platform of cromo-platino “, commented Dr. Keith D. Dawkins, Vice President and Director Médico of the Group of Cardiology, rhythm and Vascular of Boston Scientific.””Complete OMEGA family of PtCr stents, offering the Interventional cardiologist the possibility of treating patient with everolimus and paclitaxel stent metallic.”

OMEGA is available in 48 sizes with diameters of 2.25 mm 4,50 mm and lengths of 8 mm to 32 mm. Boston Scientific hosts and makes available to physicians and patients the most comprehensive range of coronary stents, the wider range of measures and the only platform with two options of drug. The company obtained the CE marking for the PROMUS Element everolimus-eluting stent in October 2009 and the eluting stent to paclitaxel TAXUS r Element Tm in May 2010.

The adoption of the CE marking for PROMUS Element Plus is scheduled for the second half of 2011.

About Boston Scientific

Boston Scientific is a company dedicated to the development, manufacture and marketing of medical devices around the world, and its products are used in a wide range of medical specialties interventionists.

warning on statements of a forward-looking nature

this press release contains statements of a forward-looking nature as described in Section 21E of the securities market law)Securities Exchange Act) 1934 American. These statements of a forward-looking nature can be identified by the use of words such as “anticipate”, “expect”, “project”, “believe”, “plan”, “plan”, “estimate” and other similar terms. These statements of a forward-looking nature are based on our beliefs, assumptions and estimates, derived from the data that was available at the time of issuing such statements and are not intended to be the guarantee of any event or performance level futures. Other statements of a forward-looking nature include those related to clinical trials, scientific activities, performance products, competitive bids, and growth investments. If the assumptions on which we base were to be incorrect, or if they materialize certain risks or doubts, the results could be substantially different expectations and forecasts expressed or implied by our forward-looking statements. In some cases, these factors have affected and could affect (alongside other factors) our ability to establish a business strategy, and may cause actual results to differ significantly from those referred to in the statements expressed in this press release. He is therefore warns the reader that it does not deposit an excessive confidence in any of our statements of a forward-looking nature.

Among others, factors that could cause such differences include: the economic, competitive, conditions of repayment and future regulation; the emergence of new products; demographic trends; the intellectual property; the litigation; financial market conditions; and business decisions that take our company and competing companies. All these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a list and a description detailed of these and other risks and important questions that could affect our future operations, see item 1A, part I, risk factors for our latest annual report on form 10-K, submitted to the Commission of stock marketIt may be updated at point 1A, part II, risk factors in the quarterly reports on form 10-Q we have presented or present later.

We disclaim any intention or obligation to update or modify publicly any affirmation of a prospective basis to reflect changes in our expectations or in events, conditions or circumstances in which those expectations could be based, or that might affect the likelihood that actual results may differ from those mentioned in the statements of a forward-looking nature. This warning statement is applicable to all prospective character statements contained in this document.